Myoediting: Toward prevention of muscular dystrophy by therapeutic genome editing

Yu Zhang, Chengzu Long, Rhonda Bassel-Duby, Eric N. Olson

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Muscular dystrophies represent a large group of genetic disorders that significantly impair quality of life and often progress to premature death. There is no effective treatment for these debilitating diseases. Most therapies, developed to date, focus on alleviating the symptoms or targeting the secondary effects, while the underlying gene mutation is still present in the human genome. The discovery and application of programmable nucleases for site-specific DNA doublestranded breaks provides a powerful tool for precise genome engineering. In particular, the CRISPR/Cas system has revolutionized the genome editing field and is providing a new path for disease treatment by targeting the disease-causing genetic mutations. In this review, we provide a historical overview of genome-editing technologies, summarize the most recent advances, and discuss potential strategies and challenges for permanently correcting genetic mutations that cause muscular dystrophies.

Original languageEnglish (US)
Pages (from-to)1205-1240
Number of pages36
JournalPhysiological Reviews
Volume98
Issue number3
DOIs
StatePublished - Jul 1 2018

Fingerprint

Muscular Dystrophies
Inborn Genetic Diseases
Mutation
CRISPR-Cas Systems
Premature Mortality
DNA Breaks
Human Genome
Therapeutics
Quality of Life
Genome
Technology
Genes
Gene Editing

ASJC Scopus subject areas

  • Physiology
  • Molecular Biology
  • Physiology (medical)

Cite this

Myoediting : Toward prevention of muscular dystrophy by therapeutic genome editing. / Zhang, Yu; Long, Chengzu; Bassel-Duby, Rhonda; Olson, Eric N.

In: Physiological Reviews, Vol. 98, No. 3, 01.07.2018, p. 1205-1240.

Research output: Contribution to journalReview article

@article{cc251bb0afa049fab07f3bc6bfef3efc,
title = "Myoediting: Toward prevention of muscular dystrophy by therapeutic genome editing",
abstract = "Muscular dystrophies represent a large group of genetic disorders that significantly impair quality of life and often progress to premature death. There is no effective treatment for these debilitating diseases. Most therapies, developed to date, focus on alleviating the symptoms or targeting the secondary effects, while the underlying gene mutation is still present in the human genome. The discovery and application of programmable nucleases for site-specific DNA doublestranded breaks provides a powerful tool for precise genome engineering. In particular, the CRISPR/Cas system has revolutionized the genome editing field and is providing a new path for disease treatment by targeting the disease-causing genetic mutations. In this review, we provide a historical overview of genome-editing technologies, summarize the most recent advances, and discuss potential strategies and challenges for permanently correcting genetic mutations that cause muscular dystrophies.",
author = "Yu Zhang and Chengzu Long and Rhonda Bassel-Duby and Olson, {Eric N.}",
year = "2018",
month = "7",
day = "1",
doi = "10.1152/physrev.00046.2017",
language = "English (US)",
volume = "98",
pages = "1205--1240",
journal = "Physiological Reviews",
issn = "0031-9333",
publisher = "American Physiological Society",
number = "3",

}

TY - JOUR

T1 - Myoediting

T2 - Toward prevention of muscular dystrophy by therapeutic genome editing

AU - Zhang, Yu

AU - Long, Chengzu

AU - Bassel-Duby, Rhonda

AU - Olson, Eric N.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Muscular dystrophies represent a large group of genetic disorders that significantly impair quality of life and often progress to premature death. There is no effective treatment for these debilitating diseases. Most therapies, developed to date, focus on alleviating the symptoms or targeting the secondary effects, while the underlying gene mutation is still present in the human genome. The discovery and application of programmable nucleases for site-specific DNA doublestranded breaks provides a powerful tool for precise genome engineering. In particular, the CRISPR/Cas system has revolutionized the genome editing field and is providing a new path for disease treatment by targeting the disease-causing genetic mutations. In this review, we provide a historical overview of genome-editing technologies, summarize the most recent advances, and discuss potential strategies and challenges for permanently correcting genetic mutations that cause muscular dystrophies.

AB - Muscular dystrophies represent a large group of genetic disorders that significantly impair quality of life and often progress to premature death. There is no effective treatment for these debilitating diseases. Most therapies, developed to date, focus on alleviating the symptoms or targeting the secondary effects, while the underlying gene mutation is still present in the human genome. The discovery and application of programmable nucleases for site-specific DNA doublestranded breaks provides a powerful tool for precise genome engineering. In particular, the CRISPR/Cas system has revolutionized the genome editing field and is providing a new path for disease treatment by targeting the disease-causing genetic mutations. In this review, we provide a historical overview of genome-editing technologies, summarize the most recent advances, and discuss potential strategies and challenges for permanently correcting genetic mutations that cause muscular dystrophies.

UR - http://www.scopus.com/inward/record.url?scp=85046797549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046797549&partnerID=8YFLogxK

U2 - 10.1152/physrev.00046.2017

DO - 10.1152/physrev.00046.2017

M3 - Review article

C2 - 29717930

AN - SCOPUS:85046797549

VL - 98

SP - 1205

EP - 1240

JO - Physiological Reviews

JF - Physiological Reviews

SN - 0031-9333

IS - 3

ER -